PIPERACILLIN AND TAZOBACTAM FOR INJECTION 3 G
PIPERACILLIN (PIPERACILLIN SODIUM) : 3 G TAZOBACTAM (TAZOBACTAM SODIUM) : 0.375 G · DIN 02402076 · AURO PHARMA INC
Health Canada status: MARKETED
What is PIPERACILLIN AND TAZOBACTAM FOR INJECTION?
PIPERACILLIN AND TAZOBACTAM FOR INJECTION 3 G contains PIPERACILLIN (PIPERACILLIN SODIUM) : 3 G TAZOBACTAM (TAZOBACTAM SODIUM) : 0.375 G. It is listed in the Health Canada Drug Product Database under DIN 02402076, held by AURO PHARMA INC, supplied as POWDER FOR SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 09-Jun-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is PIPERACILLIN AND TAZOBACTAM FOR INJECTION used for?
Piperacillin and Tazobactam for Injection (sterile piperacillin sodium/tazobactam sodium) is indicated for the treatment of patients with systemic and/or local bacterial infections, caused by piperacillin resistant, piperacillin/tazobactam susceptible, ß - lactamase producing strains of the designated microorganisms in the specified conditions listed below: INTRA - ABDOMINAL INFECTIONS, SKIN AND SKIN STRUCTURE INFECTIONS, GYNECOLOGICAL INFECTIONS, COMMUNITY-ACQUIRED LOWER RESPIRATORY TRACT INFECTIONS, NOSOCOMIAL PNEUMONIA.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02402076 |
|---|---|
| Brand name | PIPERACILLIN AND TAZOBACTAM FOR INJECTION |
| Generic / active ingredient | PIPERACILLIN (PIPERACILLIN SODIUM) : 3 G TAZOBACTAM (TAZOBACTAM SODIUM) : 0.375 G |
| Manufacturer | AURO PHARMA INC |
| Strength | 3 G |
| Dosage form | POWDER FOR SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription |
| ATC code | J01CR05 PIPERACILLIN AND BETA-LACTAMASE INHIBITOR |
| AHFS class | 08:12.16.16 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 09-Jun-2021 |
| Original market date | 2021-06-09 00:00:00 |
How is it stored and handled?
20 and 25 °C (room temperature); 2 and 8 °C (refrigerated temperatures)
How is it supplied?
10 Vials Per box
Is PIPERACILLIN AND BETA-LACTAMASE INHIBITOR in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by SANDOZ CANADA INCORPORATED, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
Check availability for PIPERACILLIN AND TAZOBACTAM FOR INJECTION
What can be used instead?
Other Canadian products sharing ATC code J01CR05 PIPERACILLIN AND BETA-LACTAMASE INHIBITOR. 16 of 52 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| PIPERACILLIN AND TAZOBACTAM FOR INJECTION | 0.375 G | POWDER FOR SOLUTION | EUGIA PHARMA INC. | MARKETED | DIN 02528703 |
| PIPERACILLIN AND TAZOBACTAM FOR INJECTION | 0.5 G | POWDER FOR SOLUTION | STERIMAX INC | MARKETED | DIN 02362635 |
| PIPERACILLIN AND TAZOBACTAM FOR INJECTION | 1.5 G | POWDER FOR SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02330547 |
| PIPERACILLIN AND TAZOBACTAM FOR INJECTION | 12 G | POWDER FOR SOLUTION | STERIMAX INC | MARKETED | DIN 02377748 |
| PIPERACILLIN AND TAZOBACTAM FOR INJECTION | 2 G | POWDER FOR SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02299623 |
| PIPERACILLIN AND TAZOBACTAM FOR INJECTION | 2 G | POWDER FOR SOLUTION | EUGIA PHARMA INC. | MARKETED | DIN 02528673 |
| PIPERACILLIN AND TAZOBACTAM FOR INJECTION | 2 G | POWDER FOR SOLUTION | AURO PHARMA INC | MARKETED | DIN 02402068 |
| PIPERACILLIN AND TAZOBACTAM FOR INJECTION | 2.00 G | POWDER FOR SOLUTION | STERIMAX INC | MARKETED | DIN 02362619 |
| PIPERACILLIN AND TAZOBACTAM FOR INJECTION | 3 G | POWDER FOR SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02299631 |
| PIPERACILLIN AND TAZOBACTAM FOR INJECTION | 3.000 G | POWDER FOR SOLUTION | STERIMAX INC | MARKETED | DIN 02362627 |
Who else supplies PIPERACILLIN AND BETA-LACTAMASE INHIBITOR worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. PIPERACILLIN AND BETA-LACTAMASE INHIBITOR appears in 16 registered pack listings across 3 markets, published on 2 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Request a quote for PIPERACILLIN AND TAZOBACTAM FOR INJECTION
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.